US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Silexion Therapeutics Corp

1.18

+0.02001.72%

Post-market: 1.190.0096+0.81%18:02 EDT

Volume:179.06K

Turnover:208.54K

Market Cap:9.93M

PE:-0.97

High:1.20

Open:1.14

Low:1.13

Close:1.16

Loading ...

Overview Company News Filings

Silexion Therapeutics Surge in Recent Trading Amid 'Promising' Preclinical Data From Tumor Drug Candidate

MT Newswires Live

BUZZ-Silexion Therapeutics soars on preclinical cancer trial data

Silexion Therapeutics reports preclinical data for SIL-204

Silexion Therapeutics Reports Strong Tumor Growth Reduction From Systemic Administration of Sil-204 in Preclinical Pancreatic Cancer Models

THOMSON REUTERS

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Top Midday Decliners

MT Newswires Live

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

BUZZ-Silexion Therapeutics falls after $5 mln public offering

Top Premarket Decliners

Silexion Therapeutics Shares Fall Premarket After $5 Million Equity Offering Announced to Fund Pre-Clinical Studies

MT Newswires Live

BRIEF-Silexion Therapeutics Announces Pricing Of $5.0 Million Public Offering

Silexion Therapeutics- Pricing of Public Offering of Aggregate 3.7 Mln Ordinary Shares and Warrants at Combined Price of $1.35 per Share and Warrant

THOMSON REUTERS

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

THOMSON REUTERS

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics

Silexion Therapeutics Shares Jump After Pancreatic-Cancer Treatment Data

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SLXN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.18,"timestamp":1743105600000,"preClose":1.16,"halted":0,"volume":179059,"hourTrading":{"tag":"盘后","latestPrice":1.1896,"preClose":1.18,"latestTime":"18:02 EDT","volume":1928,"amount":2269.9302216,"timestamp":1743112968110},"delay":0,"floatShares":5231700,"shares":8414615,"eps":-1.215216,"marketStatus":"Post-Market Trading","change":0.02,"latestTime":"03-27 18:05:34 EDT","open":1.14,"high":1.2,"low":1.1296,"amount":208538.57542990003,"amplitude":0.06069,"askPrice":1.21,"askSize":572,"bidPrice":1.15,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-1.215216,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743120000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.16,"preHourTrading":{"tag":"盘前","latestPrice":1.13,"preClose":1.16,"latestTime":"09:25 EDT","volume":3136,"amount":3678.1325503999997,"timestamp":1743081913269},"postHourTrading":{"tag":"盘后","latestPrice":1.1896,"preClose":1.18,"latestTime":"18:02 EDT","volume":1928,"amount":2269.9302216,"timestamp":1743112968110},"volumeRatio":0.657517},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5231700,"roa":"--","roe":"--","lyrEps":0.386244,"volumeRatio":0.657517,"shares":8414615,"dividePrice":0,"high":1.2,"amplitude":0.06069,"preClose":1.16,"low":1.1296,"week52Low":0.575,"pbRate":"--","week52High":122.0184,"institutionHeld":0,"latestPrice":1.18,"committee":-0.839228,"eps":-1.215216,"divideRate":0,"volume":179059,"delay":0,"ttmEps":-1.215216,"open":1.14,"prevYearClose":2.01,"prevWeekClose":1.14,"prevMonthClose":1.07,"prevQuarterClose":2.01,"fiveDayClose":1.11,"twentyDayClose":1.11,"sixtyDayClose":2.1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507548449","title":"Silexion Therapeutics Surge in Recent Trading Amid 'Promising' Preclinical Data From Tumor Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2507548449","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507548449?lang=en_us&edition=fundamental","pubTime":"2025-01-29 00:15","pubTimestamp":1738080905,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics  shares rose more than 100% in recent Tuesday trading after the company reported \"promising\" preclinical data from its tumor drug candidate, SIL-204, in mice.Based on the data, the company said the drug candidate administered in an extended-release formulation reduced tumor growth by more than 50% after 30 days, with about 50% of tumors showing complete necrosis in human pancreatic tumors.The company also said that the drug candidate administered subcutaneously inhibited tumor growth in mouse metastatic pancreatic orthotopic models.\"While the current data shows robust tumor growth inhibition, further studies aim to evaluate its impact on metastases, which the Company is cautiously optimistic about,\" the company said.Silexion said it is actively exploring how the data may be used to determine an expanded treatment strategy for certain cancers and expects to announce the details of its expanded development plan \"shortly.\"Price: 1.16, Change: +0.58, Percent Change: +","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLXN","BK4139","LENZ"],"gpt_icon":0},{"id":"2506519972","title":"BUZZ-Silexion Therapeutics soars on preclinical cancer trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2506519972","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506519972?lang=en_us&edition=fundamental","pubTime":"2025-01-28 22:13","pubTimestamp":1738073629,"startTime":"0","endTime":"0","summary":"BUZZ-Silexion Therapeutics soars on preclinical cancer trial data** Shares of drug developer Silexion Therapeutics SLXN.O rise ~125% to $1.30 premarket** SLXN says preclinical trials of its cancer treatment, SIL-204, shows significant reduction in tumor growth in pancreatic cancer models** SIL-204 reduced tumor growth by 50% and showed complete necrosis in 50% of tumors in some trials** Says SIL-204 was effective in inhibiting key cancer-causing KRAS mutations and maintained effective drug levels in the body for over 56 days** SLXN fell 88.4% in 2024, since its Nasdaq debut on Aug. 16, 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nL3N3OO0ZI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2506515267","title":"Silexion Therapeutics reports preclinical data for SIL-204","url":"https://stock-news.laohu8.com/highlight/detail?id=2506515267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506515267?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:36","pubTimestamp":1738071379,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings contribute t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-reports-preclinical-data-for-sil-204?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-reports-preclinical-data-for-sil-204?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SIL","LENZ","SLXN"],"gpt_icon":0},{"id":"2506155135","title":"Silexion Therapeutics Reports Strong Tumor Growth Reduction From Systemic Administration of Sil-204 in Preclinical Pancreatic Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2506155135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506155135?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:30","pubTimestamp":1738071002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3OO1FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2506516350","title":"Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2506516350","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506516350?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:29","pubTimestamp":1738070940,"startTime":"0","endTime":"0","summary":"New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/28/3016377/0/en/Silexion-Therapeutics-Reports-Strong-Tumor-Growth-Reduction-from-Systemic-Administration-of-SIL-204-in-Preclinical-Pancreatic-Cancer-Models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIL","LENZ","BK4139","SLXN"],"gpt_icon":0},{"id":"2504465109","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2504465109","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504465109?lang=en_us&edition=fundamental","pubTime":"2025-01-17 02:31","pubTimestamp":1737052299,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics (ATRA) reported \"compliance issues\" on Thursday involving a third-party manufacturing facility for Ebvallo, a treatment for patients with Epstein-Barr virus-positive post-transpl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["USB","BK4139","LU2237438978.USD","BK4504","BK4207","IE00BFXG1179.USD","LU0170899867.USD","BK4585","SLXN","BK4588","BK4559","ATRA"],"gpt_icon":0},{"id":"2504091454","title":"PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2504091454","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504091454?lang=en_us&edition=fundamental","pubTime":"2025-01-17 00:04","pubTimestamp":1737043440,"startTime":"0","endTime":"0","summary":"KRAS, one of the most mutated oncogenes across cancers, drives aggressive and treatment-resistant tumors. Silexion’s latest data highlights SIL-204’s ability to enhance first-line therapies, showcasing its potential to transform outcomes in these hard-to-treat cancers.The newly released data reveal significant synergy between SIL-204 and first-line chemotherapy agents, including 5-fluorouracil, irinotecan, and gemcitabine. In human pancreatic tumor cell models harboring KRAS G12D mutations, SIL-204 amplified the efficacy of these standard therapies, resulting in greater reductions in cancer cell confluence compared to chemotherapy alone. This underscores SIL-204’s potential to enhance treatment regimens for pancreatic cancer and other KRAS-driven cancers, potentially addressing a substantial unmet medical need.As KRAS-driven cancers continue to be among the most aggressive and elusive to treat, Silexion’s progress with SIL-204 positions it as an important innovator to watch in the prec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pesg-market-silexion-therapeutics-sil-160400748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SIL","SLXNW","BK4211","SLXN","HOPE","BK4139","LENZ"],"gpt_icon":0},{"id":"2503919160","title":"BUZZ-Silexion Therapeutics falls after $5 mln public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2503919160","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503919160?lang=en_us&edition=fundamental","pubTime":"2025-01-16 23:42","pubTimestamp":1737042153,"startTime":"0","endTime":"0","summary":"BUZZ-Silexion Therapeutics falls after $5 mln public offering** Shares of drug developer Silexion Therapeutics SLXN.O fall 28.2% to $1.12 ** SLXN says it is raising $5 mln through a public offering** Public offering price is $1.35/share; 13.5% discount to the stock's last close** Company plans to sue the proceeds to advance pre-clinical studies and for general corporate purposes** H.C. Wainwright & Co. is the exclusive placement agent for the offering** SLXN fell 88.3% in 2024 since its Nasdaq debut on Aug. 16, 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nL4N3OC1E9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"2503900469","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2503900469","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503900469?lang=en_us&edition=fundamental","pubTime":"2025-01-16 21:23","pubTimestamp":1737033814,"startTime":"0","endTime":"0","summary":"LuxUrban Hotels  shares tumbled nearly 48% in recent Thursday premarket activity after it reported in a regulatory filing overnight it received a Nasdaq notice that the exchange's hearings panel decided to delist the company's securities from the exchange due to noncompliance with listing requirements. The company's trading is set to be suspended Friday.Silexion Therapeutics  shares fell nearly 22% after it said late Wednesday it priced a public offering of a total of about 3.7 million of its ordinary shares and warrants to buy up to 3.7 million of ordinary shares for gross proceeds of about $5 million.Polestar Automotive Holding  stock fell 11% after it posted lower Q3 preliminary revenue from a year earlier.UnitedHealth Group  stock fell 3.4% after it reported lower-than-expected Q4 revenue.Nokia  shares slid more than 2% after Goldman Sachs downgraded it to sell from neutral with a $3.60 price target.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-premarket-decliners-132334502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1548497426.USD","LU1037948541.HKD","LU0354030438.USD","LU2125154778.USD","SG9999017495.SGD","LU0683600562.USD","LU0965509283.SGD","LU1119994496.HKD","SLXN","LU2264538146.SGD","IE00B19Z8X17.USD","LUXHP","LU0976567544.SGD","LU1718418525.SGD","LU2362541513.USD","BK4585","LU1791710582.SGD","LUXH","LU2362540622.SGD","UNH","LU1069347547.HKD","LU2089984988.USD","LU0158827781.USD","SG9999002224.SGD","LU1934455863.HKD","NOK","LU1988902786.USD","IE00BFSS8Q28.SGD","IE0002141913.USD","BK4233","LU1732799900.SGD","LU0079474960.USD","LU1066051811.HKD","LU1323610961.USD","IE00BKPKM429.USD","PSNY","LU1064131342.USD","LU0203347892.USD","SGXZ99366536.SGD","LU2244417387.USD","IE00B19Z9P08.USD","LU2361045086.USD","LU0107464264.USD","LU2361044949.HKD","LU0965508806.USD","BK4547","LU2271345857.HKD","IE00B19Z3581.USD","LU0187121727.USD","LU2125154935.USD","LU1035773651.USD"],"gpt_icon":1},{"id":"2503596865","title":"Silexion Therapeutics Shares Fall Premarket After $5 Million Equity Offering Announced to Fund Pre-Clinical Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2503596865","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503596865?lang=en_us&edition=fundamental","pubTime":"2025-01-16 17:33","pubTimestamp":1737020012,"startTime":"0","endTime":"0","summary":"Price: 1.37, Change: -0.19, Percent Change: -12.18","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EQR","LENZ","BK4585","BK4215","BK4139","BK4588","SLXN"],"gpt_icon":0},{"id":"2503988324","title":"BRIEF-Silexion Therapeutics Announces Pricing Of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2503988324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503988324?lang=en_us&edition=fundamental","pubTime":"2025-01-16 09:06","pubTimestamp":1736989564,"startTime":"0","endTime":"0","summary":"BRIEF-Silexion Therapeutics Announces Pricing Of $5.0 Million Public OfferingJan 15 (Reuters) - Silexion Therapeutics Corp SLXN.O:SILEXION THERAPEUTICS ANNOUNCES PRICING OF $5.0 MILLION PUBLIC OFFERIN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nTUA8FKGVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503988341","title":"Silexion Therapeutics- Pricing of Public Offering of Aggregate 3.7 Mln Ordinary Shares and Warrants at Combined Price of $1.35 per Share and Warrant","url":"https://stock-news.laohu8.com/highlight/detail?id=2503988341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503988341?lang=en_us&edition=fundamental","pubTime":"2025-01-16 09:00","pubTimestamp":1736989200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nTUA8FKGVG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503600794","title":"Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2503600794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503600794?lang=en_us&edition=fundamental","pubTime":"2025-01-16 09:00","pubTimestamp":1736989200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nTUA8FKGVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2503398880","title":"Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2503398880","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503398880?lang=en_us&edition=fundamental","pubTime":"2025-01-16 09:00","pubTimestamp":1736989200,"startTime":"0","endTime":"0","summary":"Cayman Islands, January 15, 2025 --Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/16/3010501/0/en/Silexion-Therapeutics-Announces-Pricing-of-5-0-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN","LENZ"],"gpt_icon":0},{"id":"2503601701","title":"Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503601701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503601701?lang=en_us&edition=fundamental","pubTime":"2025-01-16 07:45","pubTimestamp":1736984700,"startTime":"0","endTime":"0","summary":"Serina Therapeutics sold its UniverXome subsidiary in a deal finalized on Dec. 23. The biotechnology company said the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing it to enter 2025 with a debt-free balance sheet. Chief Executive Steve Ledger added that the deal will allow Serina to continue advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. Shares jump 21%, to $5.84, in postmarket trading.Powell Max said it has commenced activities to pursue acquisitions as part of its business strategy. The company is evaluating other financial communications service providers, planning to acquire companies generating $1.5 million to $5 million in gross annual revenue. It intends to retain most of the management teams of any acquired companies. Shares surge 84%, to $2.54, in after-hours trading.Silexion Therapeutics released what the company called promising preclinical data for its treatment of pancreatic cancer. The","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US5Y.BOND","US10Y.BOND","US12M.BOND","BK4585","PMAX","SER","US7Y.BOND","BK4588","US6M.BOND","US30Y.BOND","BK4112","SLXN","BK4139","US2Y.BOND","GPRO","LENZ","BK4078","BK4096","US3Y.BOND"],"gpt_icon":1},{"id":"2503067006","title":"Silexion Therapeutics Shares Jump After Pancreatic-Cancer Treatment Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2503067006","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503067006?lang=en_us&edition=fundamental","pubTime":"2025-01-16 07:05","pubTimestamp":1736982300,"startTime":"0","endTime":"0","summary":"Shares of Silexion Therapeutics surged after the company released what it called promising preclinical data for its treatment of pancreatic cancer.The stock jumped 68%, to $2.61, in after-hours trading Wednesday. Shares ended the regular session 12% lower, at $1.56, putting them down more than 98% in the last year.The biotech company said its proprietary second-generation siRNA candidate, SIL-204, demonstrated synergistic efficacy in combination with components of first-line chemotherapy for pancreatic cancer.Additional preclinical data show that the drug exhibits synergistic activity with 5-fluorouracil and irinotecan--two main components commonly used in pancreatic-cancer treatments--when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, which is the most common mutation in pancreatic cancer, the company said.Moving forward, Silexion said it will continue developing SIL-204. It plans to initiate toxicology studies with the drug within the upcoming months, as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","LENZ","BK4139"],"gpt_icon":0}],"pageSize":16,"totalPage":5,"pageCount":2,"totalSize":72}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1730520000000}}}